6493-05-6
中文名稱
己酮可可堿
英文名稱
Pentoxifylline
CAS
6493-05-6
EINECS 編號
229-374-5
分子式
C13H18N4O3
MDL 編號
MFCD00063379
分子量
278.31
MOL 文件
6493-05-6.mol
更新日期
2024/12/22 16:32:15
6493-05-6 結(jié)構(gòu)式
基本信息
中文別名
1-(5-氧代己基)可可堿3,7-二氫-3,7-二甲基-1-(5-氧己基)-1H-嘌呤-2,6-二酮
已酮可可豆堿
已酮可可堿
己酮可可堿
英文別名
3,7-DIHYDRO-3,7-DIMETHYL-1-(5-OXOHEXYL)-1H-PURINE-2,6-DIONEPENTOXIFYLLINE
PENTOXYFYLLINE
PENTOXYIFYLLINE
PENTOXYPHYLINE
PTX
TRENTAL
1-(5-Oxohexyl)-3,7-dimethylxanthine
1-(5-oxohexyl)-theobromin
1-(5-Oxohexyl)theobromine
1-(5-oxohexyl)-Theobromine
1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-
3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1h-purine-6-dione
3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)xanthine
Azupentat
BL 191
bl191
Dimethyloxohexylxanthine
所屬類別
原料藥：周圍血管擴(kuò)張藥物理化學(xué)性質(zhì)
外觀性狀白色針狀結(jié)晶。熔點(diǎn)105℃。易溶于水、苯、乙醇、氯仿，微溶于乙醇。無臭，味苦。
熔點(diǎn)98-100°C
沸點(diǎn)421.13°C (rough estimate)
密度1.1713 (rough estimate)
折射率1.6000 (estimate)
儲存條件Sealed in dry,Room Temperature
溶解度H2O: ≥43 mg/mL
酸度系數(shù)(pKa)0.50±0.70(Predicted)
形態(tài)solid
顏色white
最大波長(λmax)276nm(lit.)
Merck14,7136
CAS 數(shù)據(jù)庫6493-05-6(CAS DataBase Reference)
NIST化學(xué)物質(zhì)信息Pentoxifylline(6493-05-6)
EPA化學(xué)物質(zhì)信息1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- (6493-05-6)
制備方法
方法一
由1，3-溴氯丙烷與乙酰乙酸乙酯在80℃左右環(huán)合得到2-甲基-3-乙氧羰基-5，6-二氫吡喃，再將其開環(huán)、溴化生成1-溴-5-已酮，然后與可可堿鈉鹽縮合制成已酮可可堿。己酮可可堿價(jià)格(試劑級)
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-B0715 | 己酮可可堿 Pentoxifylline | 6493-05-6 | 500mg | 400元 |
| 2024/11/08 | HY-B0715 | 己酮可可堿 Pentoxifylline | 6493-05-6 | 10mM * 1mLin DMSO | 500元 |
| 2024/11/08 | P2050 | 己酮可可堿 Pentoxifylline | 6493-05-6 | 5g | 250元 |
常見問題列表
生物活性
Pentoxifylline (BL-191) 是一種血液流變學(xué)改善劑。Pentoxifylline 是一種具有口服活性的，非選擇性的磷酸二酯酶 (PDE) 抑制劑，具有免疫調(diào)節(jié)、抗炎、血液流變學(xué)改善、抗纖溶和抗增殖作用。Pentoxifylline 可用于研究周圍血管疾病、腦血管疾病和其他一些涉及局部微循環(huán)缺陷的疾病。靶點(diǎn)
PDE
體外研究
Pentoxifylline (0.1-50 mM; 24-48 hours) inhibits cell proliferation in a dose-dependent manner.
Pentoxifylline (0.5 mM; 12-36 hours) increases apoptosis and decreases autophagy levels in MDA-MB-231 cells.
Pentoxifylline (0.5 mM; 12-36 hours) induces autophagy in MDA-MB-231 cells.
Pentoxifylline (0.5 mM; 24-48 hours) blocks cell cycle at the G0/G1 phase.
Pentoxifylline results in high LC3-II/LC3-ratio.
Cell Autophagy Assay
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 0.1 mM, 1 mM, 5 mM , 10 mM, 50 mM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Inhibited cell proliferation in a dose-dependent manner. |
Apoptosis Analysis
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 12 hours, 24 hours, 36 hours |
| Result: | Induced apoptosis. |
Apoptosis Analysis
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Induced approximately 20-28% of cell autophagy. |
Cell Cycle Analysis
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Induced G0/G1 phase arrest. |
Western Blot Analysis
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Induced high LC3-II/LC3-ratio. |
體內(nèi)研究
Pentoxifylline (200 mg/kg; i.p.) has a protective effect on rats with transient global ischemia and could reduce cognitive impairment.
| Animal Model: | Adult male Wistar rats 12-13-weeks-old (250-300 g) |
| Dosage: | 200 mg/kg |
| Administration: | Intraperitoneal injection, at 1hr before and 3 hr after ischemia |
| Result: | Significantly improved the spatial memory and effects were significant different from those of sham-operated and vehicle groups. |